NFE2L2 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain NFE2L2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

NFE2L2 is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NFE2L2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

NFE2L2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NFE2L2 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NFE2L2 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

NFE2L2 is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NFE2L2 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NFE2L2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].